nach oben

Familial Cancer

Erschienen in:

01.06.2015 | Original Article

Exome sequencing reveals three novel candidate predisposition genes for diffuse gastric cancer

verfasst von: Iikki Donner, Tuula Kiviluoto, Ari Ristimäki, Lauri A. Aaltonen, Pia Vahteristo

Erschienen in: Familial Cancer | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Gastric cancer is the fourth most common cancer worldwide and the second leading cause of cancer mortality. Three hereditary gastric cancer syndromes have been described; hereditary diffuse gastric cancer (HDGC), familial intestinal gastric cancer (FIGC) and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS). Thirty per cent of HDGC families have heterozygous germline mutations in CDH1, which encodes E-cadherin. A germline truncating mutation in the gene encoding α-E-catenin (CTNNA1) was also recently discovered in a family with HDGC, but no other genes specifically predisposing to gastric cancer have been identified, leaving the majority of cases showing familial aggregation without a known genetic cause. The aim of this study was to find the putative gastric cancer predisposing gene defect in a family with HDGC that had previously been tested negative for mutations in CDH1. In this family, there were six cases of diffuse gastric cancer in two generations. Exome sequencing was applied to two affected family members. The shared variants which were predicted deleterious in silico and could not be found in databases or in a control set of over 4,000 individuals were Sanger sequenced in a third family member. Three candidate variants were identified: p.Glu1313Lys in Insulin receptor (INSR), p.Arg81Pro in F-box protein 24 (FBXO24) and p.Pro1146Leu in DOT1-like histone H3K79 methyltransferase (DOT1L). These variants and adjacent regions were screened for in an additional 26 gastric cancer patients with a confirmed (n = 13) or suspected (n = 13) family history of disease, but no other non-synonymous mutations were identified. This study identifies INSR, FBXO24 and DOT1L as new candidate diffuse gastric cancer susceptibility genes, which should be validated in other populations. Of these genes, INSR is of special interest as insulin signaling was recently shown to affect tumor cell invasion capability by modulating E-cadherin glycosylation.

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, et al. (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, Lyon. http://globocan.iarc.fr. Accessed on 13 Dec 2013

Zanghieri G, Gregorio CD, Sacchetti C, Fante R, Sassatelli R et al (1990) Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. Cancer 66:2047–2051CrossRefPubMed

La Vecchia C, Negri E, Franceschi S, Gentile A (1992) Family history and the risk of stomach and colorectal cancer. Cancer 70:50–55CrossRefPubMed

Palli D, Galli M, Caporaso NE, Cipriani F, Decarli A et al (1994) Family history and risk of gastric cancer in Italy. Cancer Epidemiol Biomarkers Prev 3:15–18PubMed

Caldas C, Carneiro F, Lynch HT, Yokota J, Wiesner GL et al (1999) Familial gastric cancer: overview and guidelines for management. J Med Genet 36:873–880PubMedCentralPubMed

Shinmura K, Kohno T, Takahashi M, Sasaki A, Ochiai A et al (1999) Familial gastric cancer: clinicopathological characteristics, RER phenotype and germline p53 and E-cadherin mutations. Carcinogenesis 20(6):1127–1131CrossRefPubMed

Worthley DL, Phillips KD, Wayte N, Schrader KA, Healey S et al (2012) Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut 61:774–779CrossRefPubMed

Vasen HFA, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG et al (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110:1020–1027CrossRefPubMed

Aarnio M, Salovaara R, Aaltonen LA, Mecklin JP, Järvinen HJ (1997) Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. Int J Cancer 74:551–555CrossRefPubMed

10.

Lindor NM, Greene MH (1998) The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst 90:1039–1071CrossRefPubMed

11.

Varley JM, McGown G, Thorncroft M, Tricker KJ, Teare MD et al (1995) An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation of TP53. J Med Genet 32:942–945CrossRefPubMedCentralPubMed

12.

Lauren P (1965) The two histological main types of gastric carcinoma, an attempt at a histoclinical classification. Acta Pathol Microbiol Scand 64:31–49PubMed

13.

Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) (2010) WHO classification of tumours of the digestive system, 4th edn. IARC, Lyon

14.

Kaneko S, Yoshimura T (2001) Time trend analysis of gastric cancer incidence in japan by histological types, 1975–1989. Br J Cancer 84:400CrossRefPubMedCentralPubMed

15.

Parsonnet J, Vandersteen D, Goates J, Sibley RK, Pritikin J et al (1991) Helicobacter pylori infection in intestinal-and diffuse-type gastric adenocarcinomas. J Natl Cancer Inst 83:640–643CrossRefPubMed

16.

Machado JC, Soares P, Carneiro F, Rocha A, Beck S et al (1999) E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest 79:459–465PubMed

17.

Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P et al (2010) Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 47:436–444CrossRefPubMedCentralPubMed

18.

Pharoah PD, Guilford P, Caldas C (2001) Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 121:1348–1353CrossRefPubMed

19.

Majewski IJ, Kluijt I, Cats A, Scerri TS, de Jong D et al (2013) An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol 229(4):621–629. doi:10.1002/path.4152 CrossRefPubMed

20.

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K et al (2010) The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20:1297–1303CrossRefPubMedCentralPubMed

21.

González-Pérez A, López-Bigas N (2011) Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am J Hum Genet 88:440–449CrossRefPubMedCentralPubMed

22.

Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A et al (2010) A method and server for predicting damaging missense mutations. Nat Methods 7:248–249CrossRefPubMedCentralPubMed

23.

Chen Y, Cunningham F, Rios D, McLaren WM, Smith J et al (2010) Ensembl variation resources. BMC Genom 11:293CrossRef

24.

Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4:1073–1081CrossRefPubMed

25.

Reva B, Antipin Y, Sander C (2011) Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 39:e118CrossRefPubMedCentralPubMed

26.

Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R et al (1999) Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19:3278–3288PubMedCentralPubMed

27.

Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R et al (2002) Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 277:39684–39695CrossRefPubMed

28.

Van Horn DJ, Myers MG Jr, Backer JM (1994) Direct activation of the phosphatidylinositol 3′-kinase by the insulin receptor. J Biol Chem 269:29–32PubMed

29.

Pollak M (2008) Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 8:915–928CrossRefPubMed

30.

Denley A, Wallace JC, Cosgrove LJ, Forbes BE (2003) The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review. Horm Metab Res 35:778–785CrossRefPubMed

31.

Yingmei W, Shaofang H, Wenyan T, Zhang L, Zhao J et al (2012) Mitogenic and anti-apoptotic effects of insulin in endometrial cancer are phosphatidylinositol 3-kinase/Akt dependent. Gynecol Oncol 125:734–741CrossRef

32.

de-Freitas-Junior JCM, Carvalho S, Dias AM, Oliveira P, Cabral J et al (2013) Insulin/IGF-I signaling pathways enhances tumor cell invasion through bisecting GlcNac N-glycans modulation. An interplay with E-cadherin. PLoS One 8(11):e81579CrossRefPubMedCentralPubMed

33.

Pinho SS, Figureiredo J, Cabral J (2013) E-cadherin and adherens-junctions stability in gastric carcinoma: functional implications of glycosyltransferases involving N-glycan branching biosynthesis, N-acetylglucosaminyltransferases III and V. Biochim Biophys Acta 1830:2690–2700CrossRefPubMed

34.

Cenciarelli C, Chiaur DS, Guardavaccaro D, Parks W, Vidal M et al (1999) Identification of a family of human F-box proteins. Curr Biol 9:1177–1179CrossRefPubMed

35.

Wang Z, Liu P, Inuzuka H, Wei W (2014) Roles of F-box proteins in cancer. Nat Rev Cancer 14:233–247CrossRefPubMedCentralPubMed

36.

Singer MS, Kahana A, Wolf AJ, Meisinger LL, Peterson SE et al (1998) Identification of high-copy disruptors of telomeric silencing in Saccharomyces cerevisiae. Genetics 150:613–632PubMedCentralPubMed

37.

Feng Q, Wang H, Ng HH, Erdjument-Bromage H, Tempst P et al (2002) Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol 12:1052–1058CrossRefPubMed

38.

Lacoste N, Utley RT, Hunter JM, Poirier GG, Côte J (2002) Disruptor of telomeric silencing-1 is a chromatin-specific histone H3 methyltransferase. J Biol Chem 277:30421–30424CrossRefPubMed

39.

Mueller D, Bach C, Zeisig D, Garcia-Cuellar MP, Monroe S et al (2007) A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 110:4445–4454CrossRefPubMedCentralPubMed

40.

Bitoun E, Oliver PL, Davies KE (2007) The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet 16:92–106CrossRefPubMed

41.

Mohan M, Herz HM, Takahashi YH, Lin C, Lai KC et al (2010) Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev 4:574–589CrossRef

42.

Huyen Y, Zgheib O, Ditullio RA Jr, Gorgoulis VG, Zacharatos P et al (2004) Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks. Nature 432:406–411CrossRefPubMed

43.

Wysocki R, Javaheri A, Allard S, Sha F, Côté J et al (2005) Role of Dot1-dependent histone H3 methylation in G1 and S phase DNA damage checkpoint functions of Rad9. Mol Cell Biol 25:8430–8443CrossRefPubMedCentralPubMed

44.

Okada Y, Feng Q, Lin Y, Jiang Q, Li Y et al (2005) hDOT1L links histone methylation to leukemogenesis. Cell 121:167–178 (erratum in: Cell 121:809)CrossRefPubMed

Titel: Exome sequencing reveals three novel candidate predisposition genes for diffuse gastric cancer
verfasst von: Iikki Donner
Tuula Kiviluoto
Ari Ristimäki
Lauri A. Aaltonen
Pia Vahteristo
Publikationsdatum: 01.06.2015
Verlag: Springer Netherlands
Erschienen in: Familial Cancer / Ausgabe 2/2015
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-015-9778-z

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Exome sequencing reveals three novel candidate predisposition genes for diffuse gastric cancer

Abstract

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel–Lindau (VHL) disease: clinical outcome and patterns of radiological response

The roles of AXIN2 in tumorigenesis and epigenetic regulation

Health professionals’ evaluation of delivering treatment-focused genetic testing to women newly diagnosed with breast cancer

Impact of BRCA1/2 mutation on young women’s 5-year parenthood rates: a prospective comparative study (GENEPSO-PS cohort)

Mutations of HNRNPA0 and WIF1 predispose members of a large family to multiple cancers

Defective DNA mismatch repair activity is common in sebaceous neoplasms, and may be an ineffective approach to screen for Lynch syndrome

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie